IDP-intwtLN10
General Information
DRACP ID DRACP01781
Peptide Name IDP-intwtLN10
Sequence RRRRRRRAAKVVILKKATEYVHS
Sequence Length 23
UniProt ID P04198 Q61976 P18444 P24793 P26014
PubChem CID Not available
Origin Synthetics
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients | Glioblastoma | Blastoma | EC50>100 μM | CYTELL assay | 72-96 h | Patent |
12O53, epithelial (glioblastoma, GMB), from surgical specimens from patients | Glioblastoma | Blastoma | EC50>100 μM | CYTELL assay | 72-96 h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C123H221N49O29
Absent amino acids CDFGMNPQW
Common amino acids R
Mass 324299
Pl 12.64
Basic residues 11
Acidic residues 1
Hydrophobic residues 8
Net charge 10
Boman Index -11128
Hydrophobicity -114.78
Aliphatic Index 84.78
Half Life
Mammalian: 1 hour
Yeast: 2 min
E.coli: 2 min
Extinction Coefficient cystines 1490
Absorbance 280nm 67.73
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US2020/0157150A1
Patent Title Anticancer Peptides
Other Iinformation Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status: Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017
Other Published ID AU2018311129A1 CA3071601A1 CN111436200A EP3661947A1 JP2020529429A KR20200032730A WO2019025432A1